CoreCap Advisors’s Anika Therapeutics ANIK Stock Holding History

CoreCap Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25	Closed	-$1K	–	614
2021 Q4	$1K	Buy	+25	New	+$1K	﹤0.01%	2039

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

CoreCap Advisors's ANIK Position: Q1 2022 in Review

CoreCap Advisors sold out of Anika Therapeutics (ANIK) in Q1 2022, closing a stake of 25 shares — an estimated $1K sold.

CoreCap Advisors first reported a position in ANIK in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 118 funds tracked by Wall St. Rank hold ANIK as of Q1 2022.

CoreCap Advisors reported no remaining Anika Therapeutics position as of Q1 2022 after selling out during the quarter.
CoreCap Advisors sold 25 Anika Therapeutics shares in Q1 2022, an estimated $1K.
CoreCap Advisors first reported a position in Anika Therapeutics in Q4 2021 and held it in 1 quarter.
CoreCap Advisors's Anika Therapeutics position peaked at $1K in Q4 2021.
118 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2022.

Based on CoreCap Advisors's 13F filing for Q1 2022, filed 29 Apr 2022.